Group A streptococcal vaccines: paving a path for accelerated development.
about
Accelerating the development of a group A Streptococcus vaccine: an urgent public health needBacterial glycobiology: rhamnose-containing cell wall polysaccharides in Gram-positive bacteriaPrevalence of group A streptococcal disease in North and Sub-Saharan Africa: a systematic review protocolCorrelates of Protection for M Protein-Based Vaccines against Group A StreptococcusSpyAD, a moonlighting protein of group A Streptococcus contributing to bacterial division and host cell adhesion.Group A streptococcus expresses a trio of surface proteins containing protective epitopes.Antimicrobial susceptibility patterns, emm type distribution and genetic diversity of Streptococcus pyogenes recovered in BrazilStreptococcus pyogenes emm Types and Clusters during a 7-Year Period (2007 to 2013) in Pharyngeal and Nonpharyngeal Pediatric Isolates.Co-Activation of Th17 and Antibody Responses Provides Efficient Protection against Mucosal Infection by Group A Streptococcus.Epidemiology Analysis of Streptococcus pyogenes in a Hospital in Southern Taiwan by Use of the Updated emm Cluster Typing System.Streptococcus pyogenes Employs Strain-dependent Mechanisms of C3b Inactivation to Inhibit Phagocytosis and Killing of Bacteria.Differing Efficacies of Lead Group A Streptococcal Vaccine Candidates and Full-Length M Protein in Cutaneous and Invasive Disease ModelsConserved patterns hidden within group A Streptococcus M protein hypervariability recognize human C4b-binding proteinCounteracting antibiotic resistance: breaking barriers among antibacterial strategies.Rheumatic Heart Disease in the Twenty-First Century.Acute rheumatic fever and rheumatic heart disease in resource-limited settings.Strategic development of the conserved region of the M protein and other candidates as vaccines to prevent infection with group A streptococci.Bacterial pathogens activate plasminogen to breach tissue barriers and escape from innate immunity.Development of Group A streptococcal vaccines: an unmet global health need.A systematic and functional classification of Streptococcus pyogenes that serves as a new tool for molecular typing and vaccine development.Prospective Longitudinal Analysis of Immune Responses in Pediatric Subjects After Pharyngeal Acquisition of Group A Streptococci.Historical aspects of rheumatic fever.Potential coverage of a multivalent M protein-based group A streptococcal vaccine.Preclinical safety study of a recombinant Streptococcus pyogenes vaccine formulated with aluminum adjuvant.Increased prevalence of group A streptococcus isolates in streptococcal toxic shock syndrome cases in Japan from 2010 to 2012.Linoleic and palmitoleic acid block streptokinase-mediated plasminogen activation and reduce severity of invasive group A streptococcal infection.Rheumatic heart disease: infectious disease origin, chronic care approach.Acute rheumatic fever and rheumatic heart disease.Strep: Where Do We Go From Here?Invasive and non-invasive group A β-haemolytic streptococcal infections in patients attending public sector facilities in South Africa: 2003–2015
P2860
Q26739210-249800EB-30E7-49EA-82BB-C1244723ECB2Q26765815-5D9D623D-CCCF-45A9-967B-81552DBD98F4Q26796469-DE02417B-414E-425C-A4F9-1792AC0FA37AQ27009175-5CB3DA3C-B8B2-413D-AF95-281B43B4C400Q33899739-D5DC29B7-B15B-465F-8DB6-7B3B42FEE784Q34701389-B53216F3-7346-48C3-8027-FD840BF6E5E4Q34975899-19A4DE9C-39EF-438B-B79F-A68896915021Q35757601-40D05A37-58C5-4B54-B41B-BE1D9EA0DFD0Q36234877-FCD59926-326B-4D13-BC79-BFB7ED505212Q36434400-3DF88887-0A47-4A5D-AB52-BD2B87B4353BQ36884841-C29DAE40-A812-4A95-99BF-1E6A1DD26220Q37027300-45AAD69D-9A2F-43C9-9EF2-0D45C04146A4Q37238510-EF2D7CE5-8B0E-4624-87FC-6F7E123EB89CQ38216443-1E1A60B3-B9E2-4C46-9533-556478ACCFC5Q38377791-B27D8620-4EC5-49F8-B7CF-4C999DAFF73EQ38382463-CD1BEA18-7FA8-4865-9A50-F7BDCA28F395Q38612165-D825B1FE-0B70-4D3D-BF7F-7E81582AD083Q38612236-4CB87FDC-7CC5-4498-8252-D9B81CE9E637Q38631048-7213586A-C6AD-4FEA-BCBD-BDD0F8605288Q39197885-4C77BF02-D39B-4A97-9834-60A17FF8F610Q40068749-5D3DED4D-45EB-48AD-BFDA-99D8F2B49CF3Q40173912-69F43D6B-C25B-4A3A-87E7-8312964CAAE1Q40258664-28A0C026-3632-4BCC-B9C2-744D3631BC78Q40653017-618E9DE5-86AD-4358-BB84-8160317248A7Q41471154-EE59F0E6-864C-4E54-9360-9DB5A0F72DDBQ41717747-0E3BDE29-9D5F-4388-B3AF-1B6FF9174F45Q47145955-535AFA91-4733-4FF9-9BA3-1A4F54D29EC9Q47429720-06ABCDD2-7E6F-42EE-A22D-4F918552DFC1Q54594735-E45D4669-34C9-496E-9873-7A05A88A4F96Q56928079-34BBAA92-1CD6-41ED-94EC-55A29B6B7516
P2860
Group A streptococcal vaccines: paving a path for accelerated development.
description
article científic
@ca
article scientifique
@fr
articol științific
@ro
articolo scientifico
@it
artigo científico
@gl
artigo científico
@pt
artigo científico
@pt-br
artikel ilmiah
@id
artikull shkencor
@sq
artículo científico
@es
name
Group A streptococcal vaccines: paving a path for accelerated development.
@en
type
label
Group A streptococcal vaccines: paving a path for accelerated development.
@en
prefLabel
Group A streptococcal vaccines: paving a path for accelerated development.
@en
P2093
P50
P1433
P1476
Group A streptococcal vaccines: paving a path for accelerated development.
@en
P2093
Andrew C Steer
Florian Schödel
Fran A Rubin
Joachim Maria Hombach
Jonathan R Carapetis
Kim Mulholland
Rajesh Kumar
Vincent A Fischetti
P304
P356
10.1016/J.VACCINE.2012.09.045
P407
P478
31 Suppl 2
P577
2013-04-01T00:00:00Z